In 2014, I wrote a post on topical finasteride that has since became one of the most read posts on this blog. In hindsight, this is not surprising when considering the fact that I get emails about topical finasteride at least several times a month. People really want to ditch oral finasteride and switch to the topical version in order to reduce their chances of side effects.
Local compounding pharmacies in most cities will be able to make topical finasteride for you if you ask. However, most of us are eagerly awaiting two thoroughly tested products that could be available for sale worldwide in the near future.
- The first of these two is Spanish (previously Swiss) company Polichem’s P-3074 product, which I have covered on this blog several times in the past. European Phase 3 clinical trials for P-3074 are almost completed, while US Phase 3 clinical trials are expected to be completed in May 2018. Moreover, in 2016, an Italian study found the product (when applied to the scalp twice per day) to have superior results to oral finasteride. Several other favorable studies from prior years have also been covered on this blog in the past. P-3074 is vehicled in Hydroxypropyl-Chitosan.
- The second of these two products is Canadian hair transplant clinic Hasson & Wong’s topical finasteride. This product is being manufactured in partnership with Italy’s Farmacia Parati. Without this partnership with a well known reputable pharmacy, I would have not put this product in the same category as Polichem’s product. The Hasson & Wong product is a liposomal formulation that has been modified via the attachment of silicone particles to the liposomes.
Perhaps a third company can develop nanoparticle based finasteride delivery in the future?
Dr. Hasson Topical Finasteride Update
Since 2014, Dr. Victor Hasson has provided this blog with regular updates about the status of his clinic’s topical finasteride (e.g., see here and here). Canadian hair loss sufferers have been able to obtain the product from his clinic. And Europeans have been able to access the product via Farmacia Parati. However, people in other regions of the world including the US have had no such luck. There are a number of regulatory hurdles that Dr. Hasson has been trying to overcome in order to sell in the US.
Last week, Dr. Hasson called me out of the blue and mentioned some new developments, the gist of which are highlighted in the latest blog post on his website. I did not record his call, but below are some highlights that I recollect:
- Dr. Hasson will answer any intelligent reader questions if you post them in the comments to this post.
- Hasson & Wong will no longer prescribe oral finasteride and has entirely moved to topical finasteride.
- Since February 2017, they have been using their third generation of topical finasteride.
- Results from topical finasteride (based on analysis of around 800 patients in the Vancouver, BC area over the past several years) have been at least as good as those from oral finasteride.
- Side effects from topical finasteride have so far been nonexistent.
- The Hasson & Wong clinic will post a number of updates with patient photos related to this latest development on their website in the coming weeks.
- US sales should finally become a reality in the near future. Dr. Hasson has selected some pharmacies in the US that will compound his proprietary product.
- I asked about topical dutasteride (which interests me more than topical finasteride), and Dr. Hasson mentioned that this product is next in line. He talked about some scientific reason that makes the topical dutasteride molecule even more amenable to the scalp and scalp absorption than the topical finasteride molecule. I will ask him to elaborate in the comments to this post.
- Dr. Hasson mentioned that it has been difficult for him to get his hands on sufficient quantities of dutasteride and therefore their research in that area has lagged. Results from topical dutasteride are superior to those from topical finasteride. This matches what we know regarding the difference in hair growth results between the oral versions of both drugs.